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resonance spectroscopy as monitor tool
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Abstract
Background: A plethora of treatment options have been described for canine meningoencephalitis of unknown
origin (MUO), yet a gold standard has not been established. The aim of this prospective pilot study was to document
the effect of a newly designed 30 Gray (Gy) radiation therapy (RT) protocol plus corticosteroids as treatment for focal
and multifocal MUO, to monitor clinical and imaging changes during the course of the disease with conventional
magnetic resonance imaging (MRI) and proton MR Spectroscopy (H-1 MRS) and to detect the occurrence of radiation
related side effects.
Results: Six dogs (3 with focal and 3 with multifocal lesions) were included in the study. The RT protocol used
consisted of 30 Gy in 10 fractions. The neurological status of all six dogs improved during RT, with 3 of 6 cases
returning to a normal condition. One dog was euthanized early during follow-up (<3 weeks after end of RT). Three
month follow up MRI was normal in one dog and improved in 3 dogs and H-1 MRS normalized in 4. In the dog without
improvement of the MRI lesions, the N-acetyl aspartate continued to decrease, while choline and creatine concentrations
remained stable during that time. This dog was euthanized 18 month after the end of RT due to relapse. One dog was
lost to follow up 12 month after completion of RT. The other 3 dogs are still alive at the time of writing.
Conclusions: RT with 30 Gy in 10 fractions can provide an additional option for anti-inflammatory treatment of focal
and multifocal MUO. The protocol used for treatment monitoring was feasible while no side effects of RT could
be observed during the follow up period. Moreover, H-1 MRS could represent a new and non-invasive tool to
control the progression of the disease during the treatment course.
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Background
Meningoencephalitis of unknown origin (MUO) is a term
used for ante-mortem presumptive diagnosis of non-
infectious meningoencephalomyelitis lacking definitive
histopathological confirmation [1-4]. MUO includes a het-
erogeneous group of diseases with a suspected aberrant
immune response directed against the central nervous sys-
tem such as granulomatous meningoencephalitis (GME)
[5-8], necrotizing meningoencephalitis (NME) [9], and
necrotizing leukoencephalitis (NLE) [10,11]. The aetiology
of these diseases is still unknown; however, a multitude of
causes, such as neoplastic, genetic, autoimmune, infec-
tious and toxic causes have been hypothesised but have
not yet been proven [12-16].
Diagnostic imaging, in particular magnetic resonance
imaging (MRI), plays an important role in the diagnosis
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of meningoencephalitis and the radiological features of
this disease have been extensively reported in veterinary
medicine [2,17-20]. However, MRI does not provide a
definitive diagnosis, which is only achieved by histopath-
ology. Proton magnetic resonance spectroscopy (H-1 MRS)
is a non-invasive technique, which allows the determination
of metabolites in living tissue [21]. H-1 MRS detects several
metabolites in the normal brain, such as N-acetyl aspartate
(NAA), choline (Cho), and creatine (Cr). NAA is consid-
ered a neuronal marker, and it is present only in neurons,
axons and dendrites. Cho is involved in membrane synthe-
sis and degradation, and Cr is involved in energy metabol-
ism. Under pathological conditions these metabolites may
show abnormal concentration (either absence, reduced or
increased concentration); and other metabolites, normally
not present in a healthy brain (such as lipids or lactate)
may be evident [22,23]. H-1 MRS has been used to distin-
guish neoplastic from inflammatory disease in human
patients [24,25] and has proven useful in monitoring
the evolution of inflammatory processes such as multiple
sclerosis [26]. The use of H-1 MRS in the brain of healthy
dogs has been recently published [27,28]. It has also been
used in research dogs for tumour models [29,30]. How-
ever, the clinical use of H-1 MRS in dogs with meningo-
encephalitis has so far not been described.
Various treatment options have been described for MUO,
however a gold standard has not yet been established. In a
recent meta-analysis [3] including 457 dogs from 71 studies,
the authors were unable to identify a preferred immunosup-
pressive regimen. Radiation therapy (RT) protocols with
total dosage ranging from 40–49.5 Gy, divided in fractions
of 2.4 to 4.0 Gy in combination with corticosteroids have
been described [31,32], leading to longer mean survival time
in dogs with focal forebrain signs compared to corticosteroid
monotherapy [31]. However, dogs with focal signs were not
preferentially selected in the study of Munana et al. [31],
only one dog with multifocal clinical signs was included in
the RT group and this dog was euthanized one day after
completing the RT. Sission et al. described a possible early
delayed radiation reaction in one dog that received a whole
brain RT protocol with 49.5 Gy in 15 fractions [32].
The aim of this prospective pilot study was to document
the effect of a newly designed 30 Gy RT protocol applied
in 10 fractions plus immunosuppressive dosage of cortico-
steroids as treatment for focal and multifocal MUO to
monitor the clinical and the imaging changes during the
course of the disease using MRI as well as H-1 MRS and
to detect the occurrence of radiation related side effects.
Materials and methods
Dogs recruited for this study were diagnosed with MUO
between January 2012 and June 2013 in the Neurology
Service of the Small Animal Department, Vetsuisse-
Faculty, University of Zurich, Switzerland. Inclusion criteria
included: (1) evidence of focal or multifocal brain lesions
during the neurological examination without signs of
spinal cord lesions or lesions in the peripheral nervous
system; (2) abnormal cerebrospinal fluid (CSF) (reference
interval: < 5 whit blood cells (WBCs)/μL, total protein
< 0.3 g/L); (3) negative tests for infectious diseases in the
CSF (4) evidence of focal or multifocal intra-axial le-
sions in MRI, according to previously reported features
[2,17-20]; (5) H-1 MRS of the brain; (6) follow-up MRI,
H-1 MRS, and CSF-centesis following the completion
of and 3 months after RT; (7) during the RT and follow
up period, no treatment with any other immunosuppressive
medication beside prednisolone. For all patients, owner’s in-
formed consent was obtained for treatment and follow-up.
The official Animal Welfare Officer of the university
approved the study design.
Diagnosis
All dogs underwent thorough general examination and
neurological evaluation performed either by a board-certified
neurologist or by a neurology resident. In order to quantify
the neurological changes of the patients during treatment
and follow-up period, a neurodisability score (NDS) as de-
scribed by Smith et al. [33] (Table 1) was applied at the time
of initial presentation. Serum biochemical analysis and
complete blood cell count were performed in all dogs. CSF
was collected from the cisterna cerebellomedullaris
and nucleated cell count, cytological examination and
total protein (TP) concentration were determined. Tests
performed to rule out infectious diseases included the
following: a) polymerase chain reaction (PCR) from
CSF for Toxoplasma gondii and Canine distemper
virus (Clinical Laboratory of the Vetsuisse Faculty
University of Zurich), b) real time PCR from CSF for
Neospora caninum (Laboklin GMBH und co KG Bad
Kissingen, Germany), c) European tick born encephalitis
serology from serum, and CSF ELISA (enzyme linked
immunosorbent assay) (Alomed Randolfzell –Böhringen,
Germany).
Diagnostic imaging
MRI of the brain was performed with a 3 T MRI scan-
ner (Philips Ingenia scanner, Philips AG, 8027 Zurich,
Switzerland). Conventional images included T1-weighted
(dorsal, sagittal, transverse), T2-weighted (dorsal, sagittal,
transvers), FLAIR (transverse) and T1-weighted (dorsal,
sagittal, trasverse), after contrast medium (Gadodiamid
(Omniscan®), 0.3 mmol/kg, GE Healthcare AG, 8152
Glattbrugg, Switzerland). H-1 MRS comprised single
voxel localization technique, acquiring Point-Resolved
Spectroscopy (PRESS) with long and/or short echo-time
(144 and 35 respectively). The single voxel was applied in
the center of the main lesion, avoiding contamination with
CSF and bony structures. Whenever possible, another
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single voxel was performed in the presumed normal
contralateral aspect of the brain, used for comparison.
When this was not possible (because of a diffuse lesion,
lesion with considerable mass effect to the contralateral
side, or lesion in the midline), database (using the same
spectroscopy technique) obtained in our institution from
normal healthy dogs was used.
A board certified non-blinded radiologist analysed the
following features from the MRI studies: (1) number of
lesions (focal, multifocal), (2) location, (3) margination
(ill-defined, well-defined), (4) signal intensity pattern in all
sequences compared to normal gray matter (hyperintense,
hypointense or isointense), (5) contrast enhancement
(degree: mild (defined as faintly identifiable signal increased
to surrounding tissue in T1W post-contrast images),
moderate (defined as easily identifiable signal increased
to surrounding tissue in T1W post-contrast images),
severe (defined as pronounced signal increased to sur-
rounding tissue in T1W post-contrast images); pattern:
homogeneous, heterogeneous, rim enhancement), (6)
presence or absence of perilesional oedema and its extent
(mild (defined as faintly identifiable T2W and FLAIR
hyperintense signal surrounding the lesions), moderate
(defined easily identifiable T2W and FLAIR hyperintense
signal surrounding the lesions), severe (defined as readily
visible T2W and FLAIR hyperintense signal well beyond
the margins of the lesion) (7) presence or absence of mass
effect.
LCModel software (LCModel, version 6.3, S Provencher,
Oakville, ON, Canada. Automatic quantitation of localized
in vivo 1H spectra with LCModel. NMR Biomed
2001;14:260–264.) was used to analyse the MRS data
obtained. The following metabolites were included in
this study: NAA (NAA, the sum of N-acetyl aspartate
and N-acetylaspartylglutamate), total choline (tCho, pre-
dominantly glycerophosphocholine and phosphocoline, and
creatine (Cr, the sum of creatine and phosphocreatine).
Lactate and lipids were noted if present. Metabolite ratios
compared to creatine were used: NAA/Cr, Cho/Cr, Cho/
NAA. The results in the abnormal and presumed normal
area of the brain were compared.
Treatment
Radiation therapy
Treatment planning was performed on the basis of a
three-dimensional computertomography (CT). For treat-
ment planning the Eclipse External Beam Planning system
version 10.0 (Varian Oncology Systems, Palo Alto, USA)
was used, applying the AAA-algorithm (version 10.0.28).
For planning CT and daily treatment, patients were under
general anaesthesia, positioned in sternal recumbency, and
immobilized in an individually shaped vacuum cushion
(BlueBag BodyFix, Elekta AB, Stockholm, Sweden) and
a custom-made bite block. The clinical target volume
(CTV) (whole brain or lesion) was delineated on the
CT and extended by 2 mm to define the planning target
volume (PTV). Organs at risk were segmented (eyes).
The prescribed dose was 30 Gy, delivered over two
weeks in 10 daily fractions of 3 Gy to the ICRU refer-
ence point. Radiation was given by a Clinac iX (Varian
Medical Systems, Palo Alto, USA). All 3D conformal
radiation therapy (3DCRT) plans were calculated with
6 MV photons and consisted of five fields. Treatment
was performed isocentrically with bolus and wedges to
insure dose homogeneity. For some patients intensity
modulated treatment (IMRT) was planned and delivered.
The treatment was administered as image guided radio-
therapy (IGRT) with daily orthogonal kV-imaging or cone
beam CT (CBCT). Prior to treatment, all IMRT plans
were dosimetrically verified using an Octavius®-Phantom
(PTW Freiburg, Germany). All dogs received steroids
during RT. The dosage was tapered depending on clin-
ical signs (Table 2).
Table 1 Neurodisability score as described by Smith et al. [33]
Cranial nerves Mentation Postural responses
PLR abnormal unilateral 0.5 Coma 1 Ataxic; ambulatory 1
bilateral 1 Obtunded 1 Ataxic; nonambulatory 2
Menace response abnormal unilateral 0.5 Circling/head pressing 2 Unable to stand 3
bilateral 1
Strabismus 1 Seizures Paresis
Nystagmus 1 Isolated 1 Paretic; ambulatory 1
Head tilt 1 Clusters 2 Paretic; nonambulatory 2
Facial paralysis unilateral 1 Status Epilepticus 3 Plegia 3
bilateral 0.5
Absent gag reflex 1
Dropped jaw 2
Megaoesophagus 2
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Table 2 Summary of prednisolone treatment, cerebrospinal fluid (CSF) nucleated cell count, CSF total protein and neurodisability score (initial presentation to
12 month follow up)
Prednisolone treatment
(mg/kg SID) per day
and duration of
treatment
CSF cell count (cells/ μl) CSF total protein (g/dl) Neurodisability score
Case Age
(month)
Breed Sex Before
RT1
During
RT
After
RT
Inital
presentation
End
of RT
3
months
after RT
Inital
presentation
End
of RT
3
months
after RT
Inital
presentation
Beginnig
of RT
End
of RT
3
months
after RT
6
months
after RT
9
months
after RT
12
months
after RT
1 8 French
Bulldog
fs 2.1
(12 d)
2.1
(2 d)
0.25
(7 d)
20 0.4 1 1 1 / / / /
1.5
(4 d)
0.5
(9 d)
2 9 Lagotto
Romagnolo
m 1.9
(22 d)
0.9
2(2 d)
0.13
(7 d)
16.3 3 3 0.4 0.3 0.28 2.5 1 0 0 0 0 0
0.45
(5 d)
0.07
(7 d)
0.25
(7 d)
3 36 Pug mk 3.5
(21 d)
2.2
(2 d)
0.5
(14 d)
126 4.3 4.33 1 0.3 0.33 3 4 2 1 1 1 1
2.2
(35 d)
1.1
(14 d)
0.25
(21d)
0.13
(21d)
0.07
(21d)
4 72 Weimaraner fs 4
(3 d)
2
(2 d)
0.2
(14d)
4.7 0.2 0.17 0.4 0.1 0.13 4.5 6.5 1.5 0 0 0 0
0.8
(5 d)
0.1
(14d)
0.4
(7 d)
5 156 Mixed
breed
m 3.7
(2 d)
2.4
(2 d)
0.5
(21d)
244 3 6 1.4 0.5 0.45 5.5 2.5 0 0 0 0 0
2.4
(8 d)
0.9
(12 d)
0.25
(7d)
0.13
(7d)
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Table 2 Summary of prednisolone treatment, cerebrospinal fluid (CSF) nucleated cell count, CSF total protein and neurodisability score (initial presentation to
12 month follow up) (Continued)
6 15 Chihuahua fs 4
(2 d)
2
(2 d)
0.5
(28d)
77 2 2 0.5 0.16 0.3 5 1.5 0 0 0 1 0
2
(12 d)
1
(12 d)
0.3
(21d)
0.15
(21d)
1RT: radiation therapy.
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Follow-up examinations
Follow-up
Clinical examination and the NDS were applied at the
time of initial presentation and repeated before starting
RT, after the last radiation treatment and followed by ex-
aminations at 3, 6, 9 and 12 month after RT. All follow-
up examinations were performed by one of the authors
(KB). Follow-up MRI and H-1 MRS and CSF tap were
performed after the last RT and 3 months thereafter.
Long term survival from beginning of RT to time point
of writing this study was documented.
Results
Seven dogs were enrolled prospectively in the study.
One was later excluded because post mortem examin-
ation was compatible with viral encephalitis; however
immunohistochemistry failed to demonstrate presence
of the endemic viral disease causing encephalitis
(canine adenovirus, parvovirus, canine distemper virus,
European tick-borne encephalitis virus) and of rabies
virus. The remaining 6 dogs included a French bulldog,
a Pug, a Lagotto Romagnolo, a Weimaraner, a mixed
breed and a Chihuahua. Three were spayed female and 3
were males (1 castrated and 2 sexually intact). Age at
initial presentation ranged from 9 months to 13 years
(mean 4 years, median 2 years). General clinical examin-
ation was unremarkable in all 6 dogs.
Before radiation therapy
The range of the NDS at initial presentation was variable
and all dogs had received steroid treatment prior to RT
(Table 2). One dog was treated additionally with cytosine
arabinoside (50 mg/m2 q 12 h for 2 d), but the dogs
neurological status worsened and it showed side effects
due to steroid treatment (polyuria-polydipsia, panting,
alopecia and muscle weakness). RT was then offered as
an alternative treatment. Cytosine arabinoside was not
repeated and instead RT was started 56 days after the
initial presentation (50 days after cessation of cytosine
arabinoside). Before performing the planning CT, while
the dog was free of any other immunosuppressive drug
apart from steroids, a new complete study (MRI, H1-
MRS and CSF tap) was performed. Only the latter re-
sults were included in the present prospective study and
were then compared to those performed during the
planned follow up.
The first RT was applied 3 to 56 days after starting the
medical treatment (mean 19.5 days, median 13 days).
Medical treatment before the first radiation treatment
resulted in an improved NDS in three dogs, a worsened
NDS in two (including the dog previously treated with
cytosine arabinoside) and an unchanged NDS in one.
The detailed dosages of prednisolone, CSF examinations
results, and NDS are summarized in Table 2. MRI
findings revealed 3 dogs with focal and 3 with multifocal
lesions (Table 3).
H-1 MRS in all cases revealed low concentration of
NAA when compared to the non-affected contralateral
side of the brain (Figures 1, 2 and 3). The choline was ei-
ther unchanged (2 cases, example Figure 1) or mildly in-
creased (4 cases, example Figure 2). Lipids peaks were
observed in 3 cases in the affected area (Figures 1 and
2), one of those also had a lactate peak (Figure 1). Lac-
tate was detected in one additional case. The creatine
peak tended to be rather similar in affected and non-
affected sides, or very mildly reduced. All metabolite ra-
tios before and after treatment are summarized in
Table 4.
CSF pleocytosis was present in 5 out of 6 dogs (range:
5–134 WBCs/μL reference interval: < 5 WBCs/μL) and
protein concentration was elevated in all dogs (range:
0.37 -1.41 g/L reference interval: < 0.3 g/L).
Radiation therapy
In all but one dog, the whole brain was considered as
CTV (median volume 73.2 cm3, mean 59.8 cm3, range
1.1-80.6 cm3). The median dose to the PTV was 30.4 Gy
(mean 30.4 Gy, range 27.6-31.4 Gy). Two patients were
treated with an IMRT plan, as dose to organs at risk
(eyes) was lower, while 3 patients had a regular 3D con-
formal RT (3DCRT)-plan. The median dose to the or-
gans at risk (left and right eye) was 10.4 and 10.8 Gy
(mean 10.5 Gy, range 0.1-16.5 and 10.8 Gy, range 0.1-
16.9 Gy, respectively). Overall treatment time was 14
days (mean; range 12–16 days) and time to start of treat-
ment after diagnosis was 17 days (mean; range 3 – 56
days).
Follow-up immediate after treatment
The NDS was normal in 3 dogs (2 dogs with focal lesion,
one with multifocal), improved in 2 dogs (one with focal,
one with multifocal lesion) and unchanged in one dog
(multifocal lesion) compared to the initial presentation
and also before start of RT.
All dogs included in this study had MRI follow-up im-
mediately after the last session of RT. MRI showed
marked reduction of the perilesional oedema in all cases.
Mass effect was improved in 5 out of 6 dogs. One patient
with a focal lesion in the brain stem showed complete
resolution after RT (Figure 3). Two dogs with focal lesions
showed a decrease in size of the lesion (Figure 4). In the
dogs with multifocal disease, two had improvement
and reduction in size of the lesions; while in one dog
with multifocal disease the lesions were not improved
(Figure 5). The signal intensity pattern of the remaining le-
sions in all dogs after treatment was the same as before
treatment. No new abnormalities were observed in any of
the patients included in this study.
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Table 3 Summary of the MRI findings before treatment of 6 dogs with meningoencephalitis of unknown origin,
divided into dogs with focal and multifocal lesions
Multifocal lesions (n = 3) Focal lesions (n = 3)
Location White and grey matter frontal, parietal and occipital lobe,
with thalamic involvement (1)
Brain stem to ventro-medial thalamus (2)
White matter occipital lobe and optic nerve (1) Cerebellar hemisphere (1)
Corpus nucleus caudatus and temporal lobes (1) Parietal white matter (1)
Margination Ill-defined (3) Ill-defined (3)
Signal intensity T2W and FLAIR hyperintense (3) T2W and FLAIR hyperintense (3)
T1W hypointense (3) T1W hypointense (2)
T1W isointense (1)
Contrast enhancement Mild and heterogeneous (3) Moderate heterogenous (2)
Moderate homogeneous (1)
Perilesional edema Mild (2) Mild (1)
Moderate (1) Moderate (2)
Mass effect Present (3) Present (3)
Figure 1 Pre-treatment MRI (A and C, T2W sequences, transverse and dorsal respectively) and pre-treatment H-1 MRS (B and D, single
voxel PRESS-144 on the normal and abnormal brain respectively; the red squares highlight where the voxel was located), of a Weimaraner
dog with focal MUO affecting the left thalamus extending to the mesencephalon. In A and C an ill-marginated hyperintense lesion is seen,
causing mild mass effect. When comparing B and D, it can be appreciated a clear reduction of the NAA peak, mild increase of Cho and the
presence of lactate and lipids in the affected side.
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H-1 MRS performed immediately after radiotherapy
showed evidence of recovery of the NAA concentration
in 5 cases (Figures 3 and 4). In these cases the choline
concentration was either similar to pre-treatment or slightly
reduced. One dog showed worsening on the metabolite
concentration after treatment, especially reduction in the
NAA concentration (Figure 5).
CSF in one dog was heavily contaminated with blood
rendering proper analysis impossible. For this reason, it
was not included in the results. CSF pleocytosis resolved
in all other cases and protein content dropped to normal
in 3 dogs and was reduced but above reference range in
2 dogs by the end of RT.
Except mild transient hair loss in the radiation field of
one dog about 3 weeks after end of the therapy no side ef-
fects were observed during the follow-up period of more
than 9 months. Prednisolone was reduced to 0.25-0.5 mg/kg
once daily (SID) by the end of RT (12 days) and completely
tapered in the next weeks (Table 2).
One dog was presented with relapsing neurological
signs 4 weeks after the end of RT, the owner declined a
further treatment and the dog was euthanased. Necropsy
confirmed GME and a complete depletion of lympho-
cytes and lymphocytic cuffs at the site of the lesions was
found. Co-irradiated regions in the brain, where no le-
sions were seen on MRI, had a normal histopathological
appearance.
Three-month follow-up
Five dogs were re-examined 3 months later. None of
these dogs received steroids at that time point. The three
dogs with the focal lesions on MRI and one of the dogs
with multifocal lesions had a completely normal neuro-
logical examination and a NDS of 0. One of these dogs
that initially presented due to seizures was free of seizures
after therapy without concurrent antiepileptic treatment.
The other dog with the multifocal lesions still showed
unilateral menace response deficit and unilateral reduced
Figure 2 Pre-treatment MRI (A and C, T2W transverse) and pre-treatment H-1 MRS (B and D, SV PRESS-35 on the abnormal and contralateral
presumed normal area of the brain (the red squares highlight where the voxel was located) of a mixed breed dog with focal MUO affecting
the left parietal lobe. Notice in A and C the ill-defined hyperintense lesion, with moderate perilesional oedema and moderate mass effect compressing
the left lateral ventricle. B shows mild elevation of the Cho peak, decrease of the NAA peak, and presence of lipids in the affected area.
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proprioception, but was free of seizures during the 3
months of observation (NDS 1). This dog continued on
antiepileptic medication (Phenobarbital 2.5 mg/kg BID,
Levetiracetam 20 mg/kg three times daily (TID)) due to
severe seizure activity before therapy. Serum levels of
phenobarbital were checked 3 weeks after the beginning
of the treatment and repeated every 3 months. Serum con-
centration was always within the therapeutic range.
MRI revealed improvement of the lesions (however,
not complete resolution) in 4 out of 5 of the cases. No
Figure 3 The Weimaraner of Figure 1 just after radiotherapy treatment (A: transverse T2W, B: PRESS 144 normal side; C: dorsal T2W; D:
PRESS 144 abnormal side). The H-1 MRS single voxels were positioned at the same areas as pre-treatment. Notice the complete resolution of the
lesion previously described affecting the left thalamus extending to the mesencephalon (A and C). The spectrum of the normal (B) and previously
abnormal region (D), are now very comparable, revealing a recovery of the neurons.
Table 4 Summary of the H-1 MRS findings of 6 dogs with meningoencephalitis of unknown origin treated with
radiotherapy, before, immediately after treatment and 3 month follow-up
Dogs MRS before treatment MRS after treatment MRS follow-up after 3 months
NAA/Cr Cho/Cr Lips/Lac NAA/Cr NAA/Cho Lips/Lac NAA/Cr Cho/Cr Lips/Lac
A N A N A N A N A N A N A N A N A N
1 0.9 1.2 0.3 0.26 - - 1.1 1.2 0.28 0.26 - - - - - - - -
2 0.65 1.2 0.35 0.312 - - 0.80 1.2 0.30 0.32 - - 1.1 1.2 0.33 0.34 - -
3 0.52 1.31 0.56 0.34 Lac - 0.41 1.29 0.59 0.34 - - 0.23 1.3 0.58 0.33 - -
4 0.44 1.2 0.37 0.386 Lips - 1.2 1.15 0.36 0.37 - - 1.2 1.2 0.34 0.34 - -
Lac
5 0.52 1.12 0.6 0.32 Lips - 0.83 1.2 0.45 0.3 - - 1.1 1.2 0.4 0.33 - -
6 0.45 1.09 0.49 0.33 - - 0.67 1.0 0.40 0.35 - - 0.9 1.0 0.32 0.34 - -
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new lesions were found. MRS showed complete recovery
of the Cho and NAA concentration, being equal to the
contralateral side in 4 out of 5 dogs. In the dog without
improvement of the MRI lesions, the NAA continued
to decrease, while Cho and Cr concentrations remained
stable during that time.
CSF analysis demonstrated a slight or moderate in-
crease in total protein (0.33 g/l and 0.45 g/l, respectively)
in 2/5 dogs.
Long-term outcome
Five dogs had additional clinical follow-up examinations
every 3 months for 9 (n = 1), 12 (n = 3) and 18 (n = 1)
months after RT. Three dogs were neurologically normal
in all follow-up examinations. One dog had one single
seizure episode and one dog continued to have 2–3 sei-
zures per month despite the use of antiepileptic medical
treatment and the neurological deficits noticed at the 3
months follow-up were still present. This dog had a re-
lapse 18 months after the end of RT, which was confirmed
by MRI and CSF tap. The dog did not respond to prednis-
olone (4 mg/kg SID for 2 days, followed by 3 mg/kg) and
cyclosporine (6 mg/kg BID) treatment and was euthanased
3 weeks later. The owner declined necropsy. The owners
of the 4 other dogs were contacted by telephone: one dog
was lost to follow-up after 12 months, the other 3 dogs
were still alive and according to the owners remained clin-
ically normal at the time of writing (12, 21 and 26 months
after RT). Neither early nor late onset of RT reactions
could be detected in our study population and owners de-
scribed the whole RT plan as satisfactory and without any
relevant complications.
In all patients we were always able to record good qual-
ity spectra from both the diseased and from the non-
affected sites. All the acquired spectra were successfully
studied further using the LC Model.
Discussion
This pilot study shows that the 30 Gy ionizing RT com-
bined with immunosuppressive dosage of corticosteroids
Figure 4 The mixed breed of Figure 2 after radiotherapy treatment (A and B: transverse T2W, C: H-1 MRS single voxel PRESS 35 of the
left temporal lesion). Notice in A and B a reduction in size of the lesion, as well as improvement of the perilesional oedema and mass effect
when compared to pretreatment images of Figure 2. However, the lesion was not yet resolved. C shows the MRS spectrum, which reveals
recovery of the NAA peak, reduction of the Cho peak and not longer presence of lipids, when compared to pre-treatment spectra.
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is a feasible protocol that can be considered as a thera-
peutic option not only in dogs with focal but also in
dogs with multifocal MUO. Furthermore we showed that
H-1 MRS could be applied to strengthen the clinical
suspicion achieved by means of combined data arising
from clinical and neurological examination, CSF-centesis,
conventional MRI and to monitor the disease course dur-
ing the treatment of MUO.
The survival time in our study (median of 476 days) is
in accordance with the findings by Munana et al. [31],
who found that six out of seven dogs with GME treated
with radiotherapy had a survival time of > 250 days with
a median of 404 days. Munana et al. [31] included mainly
dogs with focal GME. Only one dog with multifocal clin-
ical signs was enrolled in that study and was treated with
RT. It was euthanased immediately after the completion
of RT due to a lack of clinical response. In our study,
we included dogs with MRI features of focal and multi-
focal MUO. All our patients with focal MUO responded
favourably to RT treatment similarly to those from the
study of Munana et al. [31]. In contrast to the only study
about RT in focal GME patients, we were able to follow
patients clinically and radiologically up to 26 months.
Similar to Munana et al. [31] all our dogs received steroids
during the study period. But since neither the exact dosage
nor the duration of treatment is described in their paper,
we cannot compare the effect of this add-on treatment for
both studies. The same holds true for most studies about
medical treatment of MUO. In one study prednisolone
monotherapy (11 dogs) was compared to prednisolone in
combination with Lomustine (14 dogs) [34]: within the
first 12 months of treatment, the dosage of prednisolone
was decreased from 1.4 to 0.6 mg/kg/d compared to a
dosage reduction from 2.1 to 0.2 mg/ kg/d in dogs treated
with both. In only 4 dogs (all Lomustine group) could the
prednisolone be discontinued in that study and in only
one dog were the steroids discontinued after 3 months
[35]. In one report about NME in 7 dogs treated either
with prednisolone alone or in combination with cyclospor-
ine [36], the 4 dogs receiving both medications prednisol-
one were started with 1 mg/kg twice daily (BID), reduced
after two weeks to 0.75 mg/kg and after another 2 weeks
reduced to the final dosage of 0.5 mg/kg BID. In the dogs
with monotherapy steroid dosage was not reduced. In a
more recent study [20] prednisolone was used in combin-
ation with cytosine arabinoside for treatment of MUO: the
initial dosage of 1 mg/kg BID was completely tapered over
34 weeks. The dosage after 3 months was 0.25 mg/kg BID.
In only one case series, prednisolone was completely
replaced by cyclosporine within 2 weeks in dogs with
Figure 5 H-1 MRS single voxel PRESS 144 in a Pug dog with multifocal MUO. A: normal side before treatment, B: abnormal side before
treatment, C: abnormal side straight after radiotherapy treatment, D: abnormal side 3 months after. Notice the decrease of the NAA concentration
over time, which is very marked at 3 months.
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suspected GME. In comparison to these results, the ste-
roids in our dogs were all discontinued within 3 months
after the beginning of RT.
The MRI findings in this study agree with previously
reported findings [2,17-20]. Lowrie et al. [20] studied
the prognostic factors and outcome of dogs with MUO.
These authors showed that MRI resolution of lesions at
three months are indicative of a good outcome, but not
predictive of relapse, whilst abnormal CSF at three months
was associated with higher risk of relapse. They concluded
that the best prognostic factors were a combination of re-
peated MRI and CSF analysis, with resolution of both at
three months suggesting a good or excellent long-term
outcome. Only one dog in our study had complete MRI
resolution of the lesions previously seen over 3 months.
However, H-1 MRS showed in 5 cases that the NAA re-
covered over time while the choline concentration de-
creased and lipids were not present anymore. These
findings parallel the improvement on the clinical status
and the CSF analysis in four out of five dogs. Decreased
levels of NAA are well documented in people with in-
flammatory lesions, such as multiple sclerosis [24,37].
The reduction of NAA in acute lesions may be caused
by oedema, transient neuronal impairment or loss [24].
NAA can show a dynamic behaviour over time as it
may recover to remyeliniation [24,37] or attributed to
therapy in viral diseases [38]. In people a decrease of
NAA correlates well with increasing neurological dis-
ability and worsening clinical state [39]. Choline is re-
ported to be mildly to moderately elevated in acute
demyelination due to alteration of the cell membranes
and due to increased membrane turnover in viral dis-
eases. These findings may recover to normality during
the follow-up after acute events in multiple sclerosis
[37], or may increase during the progress of viral disease
[38]. The presence of lipids is attributed to membrane
breakdown, when fractured lipids become spectroscopic-
ally visible. Lactate is related to anaerobic glycolysis of the
brain or macrophage activation after membrane break-
down [13,15]. In this scenario, the changes seen in our
patients corresponded to inflammatory white matter
disease in people. Furthermore, the follow-up studies
allowed us to demonstrate the recovery of NAA (and
decrease of Cho in some cases), which can be corre-
lated, with the improvement of the clinical signs and
neurodisability score.
This is the first report of dogs with MUO in which
H-1 MRS is used as a diagnostic and monitoring tool.
Several authors have acknowledged the need of a non-
invasive test for the diagnosis of MUO [2,20,34]. The
preliminary results of this pilot study show that H-1
MRS is a feasible technique and provides additional in-
formation for the diagnosis of MUO and it is a valuable
tool for monitoring the disease. Further studies with
larger number of patients are necessary to assess its
validity as a prognostic factor.
H-1 MRS is also used to evaluate the potential changes
of normal brain tissue caused by radiotherapy [40-42].
At the three-month follow-up, we did not observe any
change in the normal contralateral side in any dog. In
this study no relevant side effects of RT could be de-
tected during the observation period. The fractionation
schedule of 30 Gy in 10 fractions is considered to be
standard for human patients with whole brain radiation
due to metastatic disease. With the used protocol of 30
Gy in 10 fractions the late toxicity such as radiation-
induced dementia is estimated to be 1.9%-5.2% for human
patients treated with brain metastasis, and is not high
enough to warrant withholding quality of life prolonging
whole brain RT [43].
A potential downside of this treatment protocol is the
need for repeated general anesthesia for RT and CSF col-
lection. However, this is an inevitable part of this treat-
ment protocol and we were not aware of any detrimental
effects in the present study. The risk of complications due
to the daily short and mild anaesthesia can be considered
low; no increased risks for dogs with intracranial neoplasia
undergoing RT have been reported in the literature.
A number of limitations are associated with this pilot
study. This study was not designed to assess the super-
iority of the 30 Gy RT protocol against another treatment.
Moreover the low number of dogs included and the lack of
a control group treated only with corticosteroids or with
other drugs highlights the need for further evidence-based
studies. Therefore, we cannot prove how much of the ob-
served improvement in our patients was due to steroid
treatment or was a result of the RT or a combination of
both. To achieve this, a larger randomized, blinded, super-
iority study is needed to draw meaningful conclusions. An-
other limitation of the study is that the radiologist was not
blinded to the clinical signs. However, the diagnosis of
MUO should be a combination of the knowledge of the
clinical signs, MRI and CSF findings. Histological confirm-
ation before initiation of treatment might be advocated as
the “condicio sine qua non” in order to design more inform-
ative studies about treatment of MUO. The possible com-
plications [44], owners concerns, and technical difficulties
(such as sampling vulnerable anatomical location or achiev-
ing a definitive diagnosis) are important drawbacks. Biopsy
was strongly suggested to the owners of all our patients but
none agreed to the procedure. Therefore we concur with
Granger et al. [3] that the definition of inclusion criteria
based upon clinical characteristics alone is important in
order to include a high number of dogs in such studies.
Conclusions
RT with a total dosage of 30 Gy in combination with
corticosteroids is a feasible potential additional option
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for the treatment of MUO compared to previously pub-
lished protocols. A randomized, prospective study, com-
paring outcome after RT and medical treatment, will be
the next step to approve the clinical validity of RT. Fur-
thermore, H-1 MRS is a promising non-invasive tech-
nique also in veterinary neuroradiology that provides
very useful biochemistry information and might be used
in the future as a tool for assessing prognostic factors
and treatment effectiveness.
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